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Epidermolysis bullosa simplex (EBS) is a group of
autosomal dominant inherited skin diseases caused by
mutations in either the keratin 5 (K5) or the keratin
14 (K14) genes and characterized by development of
intraepidermal skin blisters. The three major subtypes
of EBS are Weber-Cockayne, Koebner, and Dowling-
Meara, of which the Dowling-Meara form is the most
severe. We have investigated five large Danish families
with EBS and two sporadic patients with the Dowling-
Meara form of EBS. In the sporadic Dowling-Meara
EBS patients, a novel K14 mutation (N123S) and
a previously published K5 mutation (N176S) were
identified, respectively. A novel K14 mutation (K116N)
was found in three seemingly unrelated families,
whereas another family harbored a different novel K14
mutation (L143P). The last family harbored a novel
K5 mutation (L325P). The identified mutations were
Epidermolysis bullosa simplex (EBS) is a group of raregenetic skin disorders with intraepidermal cytolyticblister formation on mechanical trauma (Pearson andSpargo, 1961). Three major subtypes and various raretypes all with autosomal dominant inheritance and
additional rarer subtypes have been identified (Gedde-Dahl and
Anton-Lamprecht, 1996). The Weber-Cockayne type of EBS
(EBS-WC), with blistering restricted to hands and feet, the Koebner
tyoe (EBS-K) with generalized blister formation, and the Dowling-
Meara type (EBS-DM) characterized by severe involvement and
clumping of the basal keratin network (Anton-Lamprecht and
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not present in more than 100 normal chromosomes.
Six polymorphisms were identified in the K14 gene and
their frequencies were determined in normal controls.
These polymorphisms were used to show that the K14
K116N mutation was located in chromosomes with
the same haplotype in all three families, suggesting a
common ancestor. We observed a strict genotype-
phenotype correlation in the investigated patients as
the same mutation always resulted in a similar pheno-
type in all individuals with the mutation, but our
results also show that it is not possible to predict the
EBS phenotype merely by the location (i.e., head, rod,
or linker domains) of a mutation. The nature of
the amino acid substitution must also be taken into
account. Key words: avoidance of pseudogene co-amplifica-
tion/founder effect/skin disease. J Invest Dermatol 112:184–
190, 1999
Schnyder, 1982; Anton-Lamprecht, 1994), are the most prevalent
types of EBS. All EBS subtypes are caused by mutations in either
K5 or K14, the major keratins expressed in the basal layer of the
epidermis (Albers and Fuchs, 1987; Kitajima et al, 1989; Bonifas
et al, 1991; Vassar et al, 1991; Lane et al, 1992).
The keratins have been divided into two types according to
molecular weight and isoelectric points (Moll et al, 1982). The
type I and type II keratin genes are located in clusters on
chromosome 17 and chromosome 12, respectively (Bader et al,
1988; Lessin et al, 1988; Romano et al, 1988; Rosenberg et al,
1988, 1991; Popescu et al, 1989; Waseem et al, 1990). The keratins
have a similar protein structure consisting of a highly conserved
alpha-helical rod domain flanked by nonhelical ‘‘head’’ and ‘‘tail’’
regions in the N-terminal and C-terminal part of the protein,
respectively. Keratin molecules of type I and II readily associate in
an obligate fashion into heteromeric molecules that make up the
intermediate filaments also known as tonofilaments (reviewed by
Smack et al, 1994; Fuchs, 1996).
More than 20 missense mutations associated with EBS disorders
have been identified in K5 and K14 (Corden and McLean, 1996;
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Figure 1. Pedigrees of the five families investigated in this study. A black circle or square illustrates individuals with the disease. Unaffected
individuals are represented by open symbols. Asterisks denote members of the families that have been investigated for the presence of mutations. An
arrow indicates the index patients.
Fuchs, 1996; Nomura et al, 1996; Stephens et al, 1997; Online
Mendelian Inheritance in Man). In general, these mutations concen-
trate in different clusters, namely, the ends of the rod domain (1A
and 2B) and the L12 linker region. In addition, mutations have
been found in the H1 segment in the head region of K5. It has
previously been described that there is a correlation between the
respective EBS subtype and the location of the K5 or K14 mutations
(Letai et al, 1993).
In this study, we have investigated members from five Danish
EBS families (Fig 1), three of the WC type, two of the K type,
and two sporadic patients with the DM type of EBS. We identified
one new and one previously identified disease-associated mutation
in the K5 gene and three new disease-associated mutations in
K14. Furthermore, we investigated if a strict genotype-phenotype
correlation could be established in our patient material. In addition,
a number of different polymorphisms in K14 were identified and
their frequencies were determined in the normal population.
MATERIALS AND METHODS
Patients Five seemingly unrelated Danish families with cases of EBS-K
or EBS-WC and two sporadic Danish EBS patients were studied. In the
two sporadic EBS patients, clumping of basal keratins, the ultrastructural
characteristic of EBS-DM, was demonstrated by electron microscopy. In
the EBS-K families, development of bullae was observed at birth or in the
neonatal period, located mainly on the hands and feet including the dorsal
surfaces. In adulthood, patients had experienced blistering on other parts
of the body, e.g., the thighs or buttocks, provoked by friction. In the
EBS-WC families, development of bullae was restricted to hands and feet.
The investigated family members are indicated in the pedigrees (Fig 1). A
summary of the clinical and genetic data of the seven index patients from
this study is listed in Table I.
PCR amplification Genomic DNA was isolated from blood samples
according to standard methods (Gustafson et al, 1987) and kept at 4°C.
Using genomic DNA as template, PCR amplifications of all exons,
including part of the flanking intron sequences, in the genes for K5 and
K14 were carried out in an automated thermal cycler (Perkin Elmer, Foster
City, CA). Initially, primer pairs were used for the PCR, which turned
out to result in coamplification of the K14 pseudogene. The presence of
the pseudogene was evident by sequence analyses of these PCR products,
because both the pseudogene and the functional K14 gene sequences were
found in nonidentical regions of the two genes. To avoid this coamplification
of the K14 pseudogene during PCR amplification of the K14 functional
gene, all primer pairs subsequently used for PCR comprised mismatches
compared with the K14 pseudogene sequence. The resulting sequences
were unambiguously identified as the functional K14 gene sequence.
Likewise, primers used for amplification of K5 were designed to prevent
coamplification of the homologous gene K6 (Stephens et al, 1997). All
PCR amplifications were carried out under standard conditions in a volume
of 50 µl, except for amplification of K14, for which the PCR reaction
volume contained 4% dimethyl sulfoxide.
The resulting PCR products were subjected to bi-directional sequencing
using M13(–21) forward and M13 reverse primers as well as gene specific
primers. Sequence analyses were performed on an automated ABI 373A
sequencer (PE Applied Biosystems, Foster City, CA). The nucleotide
sequences of the primers used for PCR amplification of K5 and K14 are
listed below. All references to nucleotides or amino acids in the text are
based upon the cDNA sequence of K5 (Eckert and Rorke, 1988) and the
sequence of the K14 gene (Marchuk et al, 1984). The initiating ATG
codon is numbered as bp 1–3, and the initiating methionine is numbered
as amino acid 1.
Primers for amplification of K5 containing M13(–21) forward or M13
reverse tails (tails are underlined):
Exon 1(1): forward 59-TGTAAAACGACGGCCAGTGAGCTCTG-
TTCTCTCCAGCA-39
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reverse 59-CAGGAAACAGCTATGACCCTCCACCGCCGAAACC-
AAAT-39
Exon 1(2): forward 59-TGTAAAACGACGGCCAGTGCTATGGCT-
TTGGAGGTGGT-39
reverse 59-CAGGAAACAGCTATGACCCCTTCTTTCTCTCTCT-
TTGGC-39
Exon 2: forward 59-TGTAAAACGACGGCCAGTCTCTATCTT-
CAAACCCTGCT-39
reverse 59-CAGGAAACAGCTATGACCCCATCTGGTACCAAGA-
AGAC-39
Exon 3: forward 59-TGTAAAACGACGGCCAGTTGGCCAGAGG-
TTCATGCTAC-39
reverse 59-CAGGAAACAGCTATGACCTCAACCTTGGCCTCCA-
GCTCC-39
Exon 4: forward 59-TGTAAAACGACGGCCAGTGAGAACCAGC-
AGCCTGCAG-39
reverse 59-CAGGAAACAGCTATGACCTGAGGTGTCAGAGACA-
TGC-39
Exon 5: forward 59-TGTAAAACGACGGCCAGTATGAGATTAA-
CTTCATGAAGATG-39
reverse 59-CAGGAAACAGCTATGACCCCATTCTTAGTGTCGT-
CATG-39
Exon 6: forward 59-TGTAAAACGACGGCCAGTAATTTCCATCT-
AAACCCAAG-39
reverse 59-CAGGAAACAGCTATGACCTTTAGAACTCAGGCCC-
CTTC-39
Exon 7: forward 59-TGTAAAACGACGGCCAGTGACCCAGAAA-
CTCAGAAGGA-39
reverse 59-CAGGAAACAGCTATGACCTAGAGCAGCCTCGCTT-
TATC-39
Exon 8: forward 59-TGTAAAACGACGGCCAGTTCGAATCATGA-
GGATGGGAG-39
reverse 59-CAGGAAACAGCTATGACCTGAGACATAAGCCACAT-
TGC-39
Exon 9(1): forward 59-TGTAAAACGACGGCCAGTAAGGGGGT-
CCAGTAGAGTGC-39
reverse 59-CAGGAAACAGCTATGACCATTTGACGCTGGAGCT-
GCTA-39
Exon 9(2): forward 59-TGTAAAACGACGGCCAGTCCTAGGTGG-
TGGGCTCAGTG-39
reverse 59-CAGGAAACAGCTATGACCTTGGGTTCTCGTGTCA-
GCAG-39
Primers for amplification of K14 containing M13(–21) forward or M13
reverse tails (tails are underlined):
Exon 1: forward 59-TGTAAAACGACGGCCAGTGCAATTTACCC-
GAGCACCTTCTCTTCACTCA-39
reverse 59-CAGGAAACAGCTATGACCATCTTAAGGTCTCAGC-
GGCCTGGGGCAT-39
Exon 2: forward 59-TGTAAAACGACGGCCAGTAGGCTACAG-
TGAAGTCCAGCTTGTGAAGTCCA-39
reverse 59-CAGGAAACAGCTATGACCGGAAACACTGCTCCAA-
AAATGCCCTACTCTG-39
Exon 3: forward 59-TGTAAAACGACGGCCAGTGCACTGTGTT-
CAACCACGCCATTTTTCAA-39
reverse 59-CAGGAAACAGCTATGACCTCCTGTCTCAGCCTC-
CCAAGTAGCTGGG-39
Exon 4: forward 59-TGTAAAACGACGGCCAGTACCAATCCG-
CTGCCATGGTGGAACTCCTG-39
reverse 59-CAGGAAACAGCTATGACCGAATGCCATTCACACC-
AGAAGGCCCCAGA-39
Exon 5: forward 59-TGTAAAACGACGGCCAGTCTGCCTTCT-
GGGGCCTTCTGGTGTGAATG-39
reverse 59-CAGGAAACAGCTATGACCAGTGTGGCCGTTCTCT-
CCCTGCCAGTCCT-39
Exon 6: forward 59-TGTAAAACGACGGCCAGTTGCACCCAG-
GACTGGCAGGGAGAGAACGG-39
reverse 59-CAGGAAACAGCTATGACCTGAGAGTGCCATGGG-
GGGGGCGGACTAAG-39
Exon 7: forward 59-TGTAAAACGACGGCCAGTGTGAAGACGC-
GGCTGGAGCAGGAGAT-39
reverse 59-CAGGAAACAGCTATGACCGCCTAGACCTGCTTGG-
GGTACAGAGGGTG-39
Exon 8: forward 59-TGTAAAACGACGGCCAGTTTTCCTCAC-
CTTCTTGGCCTCCTTACTCCTG-39
reverse 59-CAGGAAACAGCTATGACCAGAGGGGATCTTCCAG-
TGGGATCTGTGTC-39
Primers for amplification of K14 cDNA [M13(–21) forward tail
underlined]:
cDNA: forward 59-TGTAAAACGACGGCCAGTGCAATTTACCC-
GAGCACCTTCTCTTCACTCA-39
reverse 59-AGGCCTGAGCGGGGCTGGGCAG
Gene-specific primers for sequencing of K14-specific PCR products:
Exon 1(1): forward: M13(–21) forward primer
reverse: 59-GCCCACCAGAAGCCCATC-39
Exon 1(2): forward: 59-GGCTATGGCGGTGGCTTC-39
reverse: M13 reverse primer
Mutation specific restriction enzyme cleavage assays A total of 55
control individuals (110 alleles) were tested for the K5 L325P mutation.
Primers introducing an ApaI-site surrounding the mutated base in exon 5
were designed (forward primer 59-ATGTCTCTGACACCTCAGTGG-
GCC-39 and reverse primer 59-GTCATCAGAGGGCCCACCTT-
GG-39) and PCR was performed, thereby amplifying both the normal and
the mutated allele if present. Restriction enzyme digestion of the resulting
PCR products with ApaI confirmed the absence of the K5 L325P mutation
in the control individuals.
The K14 mutations K116N and L143P create new restriction sites for
the enzymes MaeII and HpaII, respectively. Affected and unaffected
members of family 1 and 2 were analyzed for the K14 K116N mutation
by MaeII-digestion of K14 exon 1 amplified products confirming that only
affected individuals harbor the mutation. Likewise, affected and unaffected
members of family 3 were tested for the K14 L143P mutation by HpaII-
digestion of K14 exon 1 amplified products confirming the presence of
the mutation exclusively in affected relatives.
RESULTS
Linkage analysis Following clinical diagnosis of the EBS patients,
four of the five Danish families were tested in a linkage analysis
study in order to determine if a possible mutation was located in
the gene for K5 or in the K14 gene. In families 1–3, the disease
cosegregated with the human keratin 10 (K10) intragenic marker
(Korge et al, 1992; Mischke, 1993) located on chromosome 17q21
and did not cosegregate with chromosome 12 microsatellite markers
D12S87, D12S85, D12S90, D12S80, and D12S81 covering the K5
region, indicating a defect in K14. In family 4, on the other hand,
the situation was reversed, suggesting a mutation in the K5 gene.
Linkage analysis was not performed in family 5, because this family,
as with families 1 and 2, was found to be connected to the small
island of Læsø in Denmark. Because linkage analysis could not be
carried out in the two sporadic EBS-DM patients, mutation-
screening analyses were performed for both K5 and K14.
Mutations in the K5 gene K5 mutations were associated with
the disease in family 4 (see pedigree in Fig 1) and in case 1 of the
sporadic EBS-DM patients. Patients from family 4, all of whom
exhibit clinical signs consistent with the EBS-K type, were found
to be heterozygous for a novel mutation in the K5 gene. The
mutation, a T to C transition in exon 5 at nucleotide position 974,
results in a change from leucine to proline at codon 325 (L325P)
(Table I). Screenings of the unaffected family members by sequen-
cing showed that the mutation was absent in these individuals.
Fifty-five control individuals were tested for the L325P mutation
by a mutation-specific restriction enzyme cleavage assay using the
enzyme ApaI. None of the control individuals carried the mutation.
A previously published mutation (Stephens et al, 1997) was
identified in exon 1 of the K5 gene in case 1 of the sporadic EBS-
DM patients. This patient was found to be heterozygous for the A
to G transition at nucleotide position 527, changing an asparagine
to serine at codon 176 (N176S) (Table I). As expected, the parents
of this patient did not carry the mutation. The K14 gene sequence
of this patient was normal.
Mutations in the K14 gene In families 1–3 and 5, two novel
mutations in exon 1 of the K14 gene were found to be associated
with the disease. In the second sporadic EBS-DM patient (case 2),
a third novel K14 mutation was identified. The index patients in
families 1 (II-6), 2 (I-2), 3 (III-6), and the sporadic patient (case
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Table II. KRT14 polymorphisms and frequenciesa
Base change Amino acid change Frequency
6T.C T2T (silent) 0.53
189T.C Y63Y (silent)b 0.48
193T.C L65 L (silent)b 0.48
231C.T S77S (silent)b 0.37
280G.A A94Tb 0.48
369T.C N123N (silent)b 0.52
aThe frequencies are based upon 60 unrelated control individuals (120 alleles),
except for the T2T polymorphism that was tested in 43 individuals (86 alleles).
bThese mutations have been described previously by Marchuk et al, 1984;
Coulombe et al, 1991, and Chen et al, 1995.
2) all had a normal K5 gene sequence. The index patient III-4 in
family 5 was not screened for K5 abnormalities.
All 22 patients tested in families 1, 2, and 5 harbored the same
heterozygous base substitution in exon 1 of the K14 gene. The
mutation was a G to C transversion at nucleotide position 348,
changing lysine 116 to asparagine (K116N) (Table I). This G to
C mutation generates a new MaeII site.
All patients from the three families exhibit clinical signs consistent
with EBS-WC. PCR products from the unaffected relatives in
families 1 and 2 were tested by specific restriction enzyme cleavage
assay with MaeII in order to see if any of these individuals carried
the mutation. The unaffected relatives in family 5 were screened
for the mutation by sequencing. The K116N mutation was not
present in unaffected individuals from any of the three families.
These three families (1, 2, and 5) all turned out to originate from
the small island of Læsø in Denmark. Although the families are
not related by the pedigrees available, the identified mutation
suggests that the families are related further back than the pedi-
grees show.
In patients from family 3 (see pedigree in Fig 1) a heterozygous
T to C transition at nucleotide position 428 was identified, changing
leucine 143 to proline (L143P) (Table I). All eight examined
patients from this family exhibited clinical signs of EBS-K. The
mutation generates a new HpaII-site, which was utilized for testing
of the unaffected family members. The L143P mutation was not
present in any of the unaffected relatives in the family.
The second sporadic EBS-DM patient (case 2) carried a hetero-
zygous A to G transition at nucleotide position 368, changing
asparagine to serine at codon 123 (N123S) (Table I). Because this
patient is a foster child, we were not able to test the biologic
parents for the identified mutation.
Screening for the three mutations found in the K14 gene
(K116N, L143P, and N123S) was carried out on 60 control
individuals (120 alleles) by direct sequencing of K14 exon 1-specific
PCR products. None of the control individuals harbored the
mutations.
Polymorphisms in the KRT14 gene During the course of
sequencing the K14 gene in the families, a number of base
substitutions were identified in affected as well as unaffected
individuals in exon 1 of K14. A total of six variations was identified
(Table II). Five of these variations have previously been identified,
namely the T to C transitions at nucleotide positions 189, 193,
231, and 369 and the G to A transition at position 280 in the K14
gene sequence corresponding to Tyr63, Leu65, Ser77, Asn123, and
Ala94, respectively (Marchuk et al, 1984; Coulombe et al, 1991;
Chen et al, 1995). All these transitions cause silent mutations,
except for codon 94, in which the transition changes alanine to a
threonine residue. Alanine 94 is located in the nonhelical head
region of K14, which has been found to be dispensable for filament
assembly in in vitro studies (Coulombe et al, 1990). Thus, the A94T
mutation is not expected to have any functional effect on the K14
protein. The remaining new variation is found at position 6 and
causes a silent mutation of Thr2 due to another T to C transition.
In order to determine the frequency of these variations, 60
unrelated control individuals (120 alleles) were tested by direct
sequencing of K14 exon 1-specific PCR products. The frequencies
of the six variations are listed in Table II, showing that these
variations are common polymorphisms in the Danish population.
In addition to the above-mentioned polymorphisms, we found
a few discrepancies between the published K14 gene sequence
(GenBank acc.no. J00124) and our K14 gene sequences in exon
1. In all the Danish patients and their healthy relatives examined
in this study, we found the sequence AA instead of TT in the
nontranslated region at nucleotide position –33 and –34 upstream
for the ATG. Likewise, the sequence GC instead of CG was found
at positions 77 and 78, resulting in a change from alanine to glycine
in codon 26. This could be due to compression during the original
sequencing of the K14 gene. Alignment of the type I and II keratins
reveals that this position often is occupied by a glycine residue.
Finally, a G instead of A was always found at nucleotide position
131, changing Asn44 to a serine. Both Gly26 and Ser44 were
found in all the 60 controls.
To confirm that the identified mutations and polymorphisms are
expressed and do not originate from coamplification of the K14
pseudogene (Savtchenko et al, 1988; GenBank acc.nos. M22927
and M22928), we isolated RNA from keratinocytes and performed
oligo-dT cDNA synthesis prior to PCR amplification of the K14
cDNA with K14 specific primers. Sequencing of the resulting K14
cDNA from both a normal individual and patients representative
for the K14 K116N and L143P mutations, as well as the cDNA
from the sporadic case 2 (N123S), were carried out, confirming
the presence of the identified mutations and polymorphisms, as
well as the described K14 sequence discrepancies. Furthermore,
we subjected K14 exon 1 PCR products amplified from genomic
DNA to digestion with the restriction enzyme TaqI. This enzyme
cleaves exon 1 in the K14 pseudogene, if present, but leaves exon
1 in the functional K14 gene intact. Subsequent PAGE of the
digested PCR products showed no bands corresponding to the
expected length of the pseudogene digestion products, supporting
that the K14 pseudogene was not coamplified during the PCR
reaction. In accordance with this, we see no contaminating
pseudogene sequence surrounding the two positions in exon 1,
where the pseudogene has 3-nucleotide deletions compared with
the K14 gene sequence.
Variations also appeared in the coding sequence of the K5 gene
in both affected and unaffected individuals. These variations have,
however, not been investigated further.
Determination of haplotypes in EBS families with K14
mutations Characterization of the six K14 polymorphisms
described above facilitated determination of the haplotypes in
affected individuals carrying the K14 K116N mutation in families
1, 2, and 5 from the island of Læsø. In all three families, an identical
haplotype of the mutant chromosome was found in affected
individuals indicating a common ancestor with the mutation. A
different haplotype of the mutant chromosome was found in family
3, harboring the L143P mutation.
DISCUSSION
At present 15 (K5) and 16 (K14) different disease-causing missense
mutations have been identified in the genes for K5 or K14 in
patients with EBS, and a correlation between the location of the
mutation in the keratin gene and the severity of the disease has
been suggested (Letai et al, 1993; Humphries et al, 1996; Uttam
et al, 1996; Fuchs, 1997; Irvine et al, 1997; Stephens et al, 1997;
Online Mendelian Inheritance in Man). Our purpose with this
study was to investigate the mutational spectrum in Danish EBS
patients, to evaluate the genotype-phenotype relationship, and in
particular to analyze whether patients from large kindreds with
identical disease-causing mutations always exhibit the same EBS
type.
All previously characterized EBS-causing mutations are clustered
in four regions in the keratin 5 and 14 molecules: the H1 domain
of the head region (only for type II keratins), the two segments
(1A and 2B) of the rod domain, and the linker region L12. Typically,
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EBS-DM-associated mutations reside in the highly conserved ends
of the 1A or 2B segments, whereas EBS-K-associated mutations
are located more centrally in the rod domain. EBS-WC mutations
are most frequently found in the linker region L12, in the H1
domain of the molecule (K5), or in the 2B segment (K14).
Consistent with these earlier findings, the mutations identified
in our two sporadic EBS-DM patients, N176S in K5 and N123S
in K14, are located at homologous positions in the beginning of
the 1A domain in the two genes. This asparagine residue is highly
conserved in the keratins and other intermediate filament proteins
such as vimentin, lamin C, and snail intermediate filament protein.
The K14 N123S mutation is situated in a cluster of previously
described K14 mutations (Q120R, R125C/H/S, and Y129D) that
all cause EBS-DM (Coulombe et al, 1991; Chen et al, 1995; Chan
et al, 1996). Because both N176S and N123S mutations cause an
identical amino acid substitution, one would expect the functional
significance of the two mutations to be similar, resulting in an
identical disease phenotype, as observed in the two sporadic EBS-
DM patients in this study. The K5 N176S mutation, however, has
recently been described in a sporadic patient with clinical findings
consistent with EBS-DM, except that no clumping of keratin
filaments was seen by electron microscopy (Stephens et al, 1997).
Our patient carrying this mutation, as well as our patient with the
K14 N123S mutation, both showed the typical clinical features of
the EBS-DM type and clumping of the basal keratins.
Both our families (3 and 4) with EBS-K have mutations that are
located more centrally in the rod domain, where mutations associ-
ated with EBS-WC have previously been identified. The
K14 L143P mutation observed in family 3 is located at the ‘‘d’’
position in the heptad repeat N-X-X-L-E-X-K (a-b-c-d-e-f-g) of
the 1A segment. This leucine residue is highly conserved among
the keratins and is thought to have hydrophobic interaction with
the residue at the ‘‘a’’ position in K5, meaning that the proline at
position 143 should interact with asparagine 193 in K5 (Hovnanian
et al, 1993). Interestingly, a N193K mutation involving the proposed
partner residue of the substituted leucine 143 has been identified
in the K5 gene of EBS patients with a milder phenotype (Humphries
et al, 1996).1 In addition, an E144A mutation associated with
recessive EBS-WC has been identified in this region of K14
(Hovnanian et al, 1993).
The K5 L325P mutation that we observed in family 4 with the
EBS-K type, is also located in a region harboring a cluster of
mutations that all have been observed in patients with EBS-WC.
In fact, the L325P mutation is the fifth mutation identified in a
cluster of K5 EBS-WC mutations (M327T, D328 V, N329K,
R331C) situated in the L12 linker region (Rugg et al, 1993; Chan
et al, 1994; Matsuki et al, 1995). Leu325 is highly conserved among
the type II keratins and is homologous to Val270 situated in L12
in K14, which has also been found to be mutated in EBS-WC
(V270M) (Rugg et al, 1993). The L325P mutation in the L12
region is likely to affect the flexibility and structure of this nonhelical
region, and thereby disrupt the lateral associations between keratin
heterodimers. Interestingly, a very recent publication describes
another EBS-K mutation in this region of K5, changing Val323 to
an alanine (Galligan et al, 1998).
At first glance, it may seem strange that both our families with
the EBS-K have mutations that on the basis of their location would
be suspected to result in the milder localized EBS-WC. The fact
that all 12 investigated members of families 3 and 4 have the same
clinical phenotype, namely EBS-K, excludes the possibility of
a misclassification. This observation supports a strict genotype-
phenotype correlation in EBS, namely in the sense that the same
mutation will always result in a single phenotype in all individuals
with the mutation. Furthermore, our findings illustrate that it is
not possible to predict the resulting phenotype merely by the
1Smith FJD, Morley SM, Rugg EL, et al: Clustering of epidermolysis
bullosa simplex mutations in relation to disease phenotype: Data from
Weber-Cockayne EBS. J Invest Dermatol 101:481A, 1993 (abstr.)
position of a mutation in one of the traditional domains. The nature
of the amino acid substitution is very important in determining the
molecular consequences of the mutation, and thus the EBS type.
The K14 L143P mutation is expected to severely impair or prevent
stabilization of the coiled-coil structure of the K14/K5 heterodimer
due to kinks in the alpha-helix, and thus have drastic functional
consequences on the keratin molecule, whereas the K14 E144A
and K5 N193K merely affect the hydrophobic interactions between
the heptad repeats of the alpha-helical segments, and thus have a
less drastic functional effect. Hence, it is not surprising that a more
severe phenotype is seen in patients with the K14 L143P mutation.
In a similar way, it can be argued that the K5 L325P mutation
must have a more severe effect than the EBS-WC mutations
previously observed in the L12 region.
The K14 K116N mutation that we identified in the three families
with EBS-WC is located in the beginning of the 1A segment and,
consequently, it cannot be defined as a typical K14 EBS-WC
mutation. Lys116 is highly conserved among the type I keratins,
whereas the homologous positions in type II keratins are occupied
by an arginine, suggesting that a basic amino acid in this position
may be important. Another EBS-WC mutation (M119I), however,
has been found in this region of K14 (Chen et al, 1995; Hu et al,
1997). Patients heterozygous for this M119I mutation have the
EBS-WC phenotype, whereas patients homozygous for M119I
have a more severe phenotype resembling EBS-DM. Interestingly,
as for Lys116 in K14, Met119 is conserved among type I keratins,
whereas an isoleucine is conserved at the homologous position
among type II keratins. Thus, methionine and isoleucine are not
interchangeable at these homologous positions in the two molecules
without disturbing the keratin filament assembly.
Just as observed in families 3 and 4 with the EBS-K form, all
24 investigated patients from the three families (1, 2, and 5) exhibit
similar clinical symptoms (EBS-WC). The fact that the K14 K116N
mutation was found in three of the five Danish families could
mean that this mutation accounts for a significant proportion of
the EBS mutations in Denmark. All three families, however, turned
out to be connected to the small island of Læsø, and share the
same haplotype of the mutant chromosome, suggesting that this is
merely the result of a local founder effect. In fact, clinical EBS
studies have been conducted in Denmark focusing on the high
incidence of EBS on the island of Læsø, where the disease for
generations has been referred to as the ‘‘Læsø-disease’’ (Bartels,
1939; Bu¨low and Nørholm-Pedersen, 1953; Nørholm-Pedersen
and Nielsen, 1953). It was suggested that these EBS families with
a connection to Læsø had a common ancestor with the disease,
although the available pedigrees of the families could not be
connected. The EBS-WC families in this study are most probably
descendants of the investigated Læsø families in this old study, and
our results provide a molecular support for the relatedness between
the families and illustrates the usefulness of the six characterized
polymorphisms in exon 1 of the K14 gene in this study.
In conclusion, this study shows that there is a strict genotype-
phenotype correlation in EBS, but that a more detailed evaluation
of the nature of the mutations than merely assignment to the
domains of the keratin protein is needed to make genotype-
phenotype predictions possible.
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